men stopped responding main treatment options researchers found small proportion men described super responders remained trial ended despite poor prognosis treatment week reported drug immunotherapy uses immune systems recognize attack cancer cells standard treatment cancers melanomas tested found 20 men advanced prostate cancer responded drug pembrolizumab saw tumors actually shrink disappear altogether relatively small number gained years extra life study journal clinical oncology found 19 saw evidence improvement patients study lived average months drug phase ii clinical trial led institute cancer research royal marsden involved 258 men advanced prostate cancer run options treatment dramatic responses seen patients tumors mutations genes